Chapter 6. Targeting of Adenoviral Gene Therapy Vectors: The Flexibility of Chemical and Molecular Conjugation
- David T. Curiel M.D.,
- Joanne T. Douglas Ph.D.
Published Online: 31 MAR 2003
DOI: 10.1002/0471234303.ch6
Copyright © 2002 John Wiley & Sons, Inc.
Book Title
Vector Targeting for Therapeutic Gene Delivery
Additional Information
How to Cite
Haisma, H. J. and Rots, M. G. (2003) Targeting of Adenoviral Gene Therapy Vectors: The Flexibility of Chemical and Molecular Conjugation, in Vector Targeting for Therapeutic Gene Delivery (eds D. T. Curiel and J. T. Douglas), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/0471234303.ch6
Editor Information
Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, The University of Alabama at Birmingham, USA
Publication History
- Published Online: 31 MAR 2003
- Published Print: 9 AUG 2002
ISBN Information
Print ISBN: 9780471434795
Online ISBN: 9780471234302
- Summary
- Chapter
Keywords:
- adenovirus;
- targeting;
- gene therapy;
- peptide;
- ligand;
- antibody;
- polyethylene glycol;
- bispecific
Summary
Physically targeted adenoviral vectors may be produced by chemical modification of the viral capsid or by the association of a bispecific molecule directed against the viral capsid and the target. Physical modification has the advantage of high flexibility and the readily availability of targeting ligands. The targeted vectors have shown selective gene transfer both in vitro as well as in vivo in animal models. They exhibit a reduction of gene transfer into non-target tissues, i.e. the liver. The increased specificity allows a reduction of dose which in turn should reduce side effects associated with adenoviral administration.